Company: NCNA
Filing Date: 2025-04-29
Form Type: F-1/A
Source: 0001193125-25-103135
Chunk: 30

Company: NuCana plc
Filing Date: 2025-04-29
Form: F-1/A
Chunk 30
---
0.8 million, respectively, after deducting the estimated Placement Agent fees and
estimated offering expenses payable by us, and assuming no issuance of any Pre-Funded Warrants and assuming no exercise of the Warrants.

However, because this is a best efforts offering and there is no minimum offering amount required as a condition to the closing of this
offering, the actual offering amount, the Placement Agent fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus, and we may not sell any or
all of the securities we are offering. As a result, we may receive significantly less in net proceeds.

We intend to use the net proceeds
of this offering, together with our existing cash and cash equivalents, to fund activities relating to the advancement of our drug discovery and development programs, and for other general corporate purposes, including, but not limited to, working
capital, capital expenditures, investments, acquisitions, should we choose to pursue any, and collaborations.

This expected use of the
net proceeds from this offering and our existing cash and cash equivalents represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. The amounts and
timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and commercialization efforts, the status of and results from clinical trials, any collaborations that we may enter
into with third parties for our product candidates and any unforeseen cash needs. Moreover, our estimates of the costs to fund our trials are based on the current designs of the trials. If we were to modify the design of any of these trials, for
instance, to increase the number of patients in the trials, our costs to fund the trials could increase. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.

Based on our planned use of the net proceeds of this offering and our current cash and cash equivalents, we estimate that such funds will be
sufficient to enable us to fund our operating expenses and capital expenditure requirements at least through 2026. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner
than we currently expect.

Pending specific utilization of the net proceeds as described above, we intend to invest the net proceeds from
this offering in short- and intermediate-term interest-bearing obligations and certificates of deposit.

We have not determined the